Sagar Lonial, MD, and Alessandra Tedeschi, MD, on CLL/SLL: Results From the RESONATE-2 Trial
2015 ASH Annual Meeting
Sagar Lonial, MD, of the Emory University School of Medicine, and Alessandra Tedeschi, MD, of the Azienda Ospedaliera Niguarda Cà Granda, discuss this international study of ibrutinib vs chlorambucil in patients 65 years and older with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma (Abstract 495).
Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and John F. Gerecitano, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss a phase I study of venetoclax monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma, including updated safety and efficacy data (Abstract 254).
James Foran, MD
James Foran, MD, of the Mayo Clinic Cancer Center, discusses two key studies on clofarabine: as a single agent for induction and postremission therapy in newly diagnosed AML, and as the basis for consolidation in nonfavorable AML (Abstracts 217 and 218).
Sagar Lonial, MD
Sagar Lonial, MD, of Emory University School of Medicine, summarizes his educational session on this vital topic.
Olivier Casasnovas, MD
Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses in French a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with advanced Hodgkin lymphoma (Abstract 577).
Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses an additional analysis of a phase II study of azacitidine combined with lenalidomide or with vorinostat vs azacitidine monotherapy in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia (Abstract 908).